Sage Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018 - 2012
Net Income	-541.49	-532.78	-457.89	606.07	-680.24	Upgrade
Depreciation & Amortization	1.39	1.12	4.18	2.63	2.28	Upgrade
Share-Based Compensation	73.37	61.6	104.63	95.99	153.23	Upgrade
Other Operating Activities	-73.86	10.02	-29.1	-40.42	-3.98	Upgrade
Operating Cash Flow	-540.59	-460.04	-378.18	664.28	-528.71	Upgrade
Capital Expenditures	-0.55	-0.94	-0.37	-0.35	-5.75	Upgrade
Change in Investments	443.47	326.37	-1,002.08	443.03	-137.41	Upgrade
Investing Cash Flow	442.91	325.43	-1,002.45	442.68	-143.16	Upgrade
Share Issuance / Repurchase	6.93	3.11	14.72	426.76	610.13	Upgrade
Other Financing Activities	-0.9	-0.04	-1.39	-	-2.5	Upgrade
Financing Cash Flow	6.03	3.07	13.33	426.76	607.62	Upgrade
Net Cash Flow	-91.65	-131.53	-1,367.3	1,534	-64.24	Upgrade
Free Cash Flow	-541.14	-460.97	-378.55	663.94	-534.46	Upgrade
Free Cash Flow Margin	-625.92%	-5997.57%	-6001.17%	59.59%	-7781.84%	Upgrade
Free Cash Flow Per Share	-9.04	-7.77	-6.45	12.77	-10.51	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).